Gainers

• Scinai Immunotherapeutics (NASDAQ:SCNI) shares rose 25.3% to $2.08 during Friday's after-market session. The market value of their outstanding shares is at $1.1 million.
• Corbus Pharmaceuticals (NASDAQ:CRBP) stock rose 14.9% to $9.33. The market value of their outstanding shares is at $159.3 million.
• Camp4 Therapeutics (NASDAQ:CAMP) shares increased by 7.99% to $4.59. The market value of their outstanding shares is at $272.3 million.
• SI-BONE (NASDAQ:SIBN) stock increased by 5.49% to $19.39. The company's market cap stands at $811.5 million.
• Bullfrog AI Hldgs (NASDAQ:BFRG) shares increased by 5.24% to $0.49. The company's market cap stands at $9.0 million.
• Moleculin Biotech (NASDAQ:MBRX) shares rose 4.88% to $0.75. The market value of their outstanding shares is at $16.1 million.

Losers

• Olema Pharmaceuticals (NASDAQ:OLMA) shares declined by 22.9% to $7.88 during Friday's after-market session. The market value of their outstanding shares is at $935.3 million.
• Turn Therapeutics (NASDAQ:TTRX) stock declined by 6.86% to $11.82. The market value of their outstanding shares is at $406.3 million.
• Beyond Air (NASDAQ:XAIR) shares fell 6.26% to $3.0. The company's market cap stands at $3.0 million.
• Biodexa Pharmaceuticals (NASDAQ:BDRX) shares fell 6.16% to $1.22. The company's, H1 earnings came out today.
• Dogwood Therapeutics (NASDAQ:DWTX) shares fell 5.68% to $1.83. The market value of their outstanding shares is at $63.9 million.
• Envoy Medical (NASDAQ:COCH) shares fell 5.3% to $0.71. The company's market cap stands at $54.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.